Bridget Hindman, PhD

Bridget Hindman, PhD SENIOR CONSULTANT, MEDICAL WRITER

Bridget Hindman has more than four years of medical writing experience in the pharmaceutical industry. She has authored and led the development of content for regulatory submissions, manuscripts, and intellectual property documents for pharmaceutical agents, including small molecules, cell/gene therapy, and medical devices across oncology, pain, cardiac, neurology, endocrinology, autoimmune, ophthalmology, and other indications across all phases of development from first-in-human to registration-enabling Phase III. She has experience drafting both preclinical and clinical manuscripts and has collaborated with and coordinated investigators across multiple study sites to present data and explore potential new treatment paradigms via novel drug combinations. In the regulatory sphere, Bridget has authored multiple successful orphan drug designation requests across different indications, IND submissions, briefing packages for Pre-IND and Type C meetings, CSRs, and clinician-focused documents, including Investigator Brochures and trial protocols. 

Before joining Halloran, Bridget was the Director of Intellectual Property and Medical Writing at Arog Pharmaceuticals, where she oversaw all medical writing efforts and managed and developed a diverse patent portfolio for a small-molecule tyrosine kinase inhibitor in Phase III trials, primarily developed for oncology indications. Before that, she was a Regular Fellow at the National Institute for Occupational Safety and Health, working in the Toxicology and Molecular Biology Branch, focusing on particulate-related pulmonary toxicology, where she developed preclinical models and assays. 

Bridget holds a BS in Molecular Biology and Criminology from the University of Texas, and a PhD in Cancer Cell Biology from West Virginia University.